Brokers Offer Predictions for Aldeyra Therapeutics, Inc’s FY2028 Earnings (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report) – Analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Tuesday, March 12th. HC Wainwright analyst M. Caufield anticipates that the biotechnology company will post earnings of $0.56 per share for the year. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.29) per share.
Separately, StockNews.com upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 29th.
Get Our Latest Stock Report on Aldeyra Therapeutics
Aldeyra Therapeutics Stock Performance
Shares of ALDX opened at $2.90 on Wednesday. Aldeyra Therapeutics has a 1 year low of $1.42 and a 1 year high of $11.97. The company has a market cap of $170.81 million, a price-to-earnings ratio of -4.53 and a beta of 1.53. The firm has a fifty day moving average of $3.37 and a 200-day moving average of $3.86.
Insiders Place Their Bets
In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the transaction, the chief executive officer now owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the transaction, the chief executive officer now directly owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Bruce Greenberg sold 13,201 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.41, for a total value of $45,015.41. Following the transaction, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The disclosure for this sale can be found here. 7.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Aldeyra Therapeutics
Several large investors have recently made changes to their positions in ALDX. Ameritas Investment Partners Inc. purchased a new position in Aldeyra Therapeutics in the second quarter valued at about $32,000. Tower Research Capital LLC TRC grew its position in Aldeyra Therapeutics by 47,866.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 4,308 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Aldeyra Therapeutics during the 1st quarter valued at $57,000. UBS Group AG raised its holdings in Aldeyra Therapeutics by 256.0% during the first quarter. UBS Group AG now owns 6,408 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 4,608 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth about $71,000. Institutional investors own 66.62% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Read More
Receive News & Ratings for Aldeyra Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aldeyra Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
